Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 3, 2026, 12:02 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Patch 2 Clear all
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Project Impact 2: A Culturally Tailored Smoking Cessation Intervention for Latino Smokers

NCT02596711
View directory record Official record
Conditions
Tobacco Use Cessation, Cancer Prevention
Interventions
Nicotine Patch, Questionnaires, Carbon Monoxide (CO) Test, Health Education and Handouts, Culturally Tailored Reading Materials, Counseling Sessions
Drug · Behavioral · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 9, 2020 · Synced Sep 3, 2026, 12:02 AM EDT
Completed Not applicable Interventional

Development of a Tailored Smoking Cessation Program for Individuals With HIV Infection in Washington, D.C.

NCT04594109
View directory record Official record
Conditions
Tobacco Smoking
Interventions
Tailored behavioral counseling, Standard of Care
Behavioral
Lead sponsor
Colorado State University
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Apr 18, 2023 · Synced Sep 3, 2026, 12:02 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Phase II A Trial of Curcumin Among Patients With Prevalent Subclinical Neoplastic Lesions (Aberrant Crypt Foci)

NCT00365209
View directory record Official record
Conditions
Healthy, no Evidence of Disease, Tobacco Use Disorder
Interventions
laboratory biomarker analysis, pharmacological study, curcumin
Other · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
40 Years and older
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2011
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Aug 26, 2015 · Synced Sep 3, 2026, 12:02 AM EDT
Active, not recruiting Not applicable Interventional

Insertable Cardiac Monitor-Guided Early Intervention to Reduce Atrial Fibrillation Burden Following Catheter Ablation

NCT04922281
View directory record Official record
Conditions
Atrial Fibrillation, Cardiovascular Diseases, Heart Diseases, Arrhythmias, Cardiac, Pathologic Processes
Interventions
Insertable Cardiac Monitor or external non-invasive LT-ECG patch
Device
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Oct 13, 2025 · Synced Sep 3, 2026, 12:02 AM EDT
Terminated Not applicable Interventional Results available

SPIRIT Small Vessel Registry

NCT00783796
View directory record Official record
Conditions
Coronary Artery Disease, Atherosclerosis, Myocardial Ischemia
Interventions
2.25 mm XIENCE V® Everolimus Eluting Coronary Stent System
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
34
States / cities
Scottsdale, Arizona • Little Rock, Arkansas • Washington D.C., District of Columbia + 29 more
Source: ClinicalTrials.gov public record
Updated May 7, 2019 · Synced Sep 3, 2026, 12:02 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of GTR in Comparison to Copaxone®

NCT01489254
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Glatiramer Acetate (GTR), Glatiramer Acetate (Copaxone®), Placebo
Drug
Lead sponsor
Synthon BV
Industry
Eligibility
18 Years to 55 Years
Enrollment
794 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
7
States / cities
Irvine, California • Port Charlotte, Florida • Sunrise, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 28, 2016 · Synced Sep 3, 2026, 12:02 AM EDT
Completed Phase 2 Interventional Results available

Everolimus for Treatment of Disfiguring Cutaneous Lesions in Neurofibromatosis1 CRAD001CUS232T

NCT02332902
View directory record Official record
Conditions
Neurofibromatosis 1
Interventions
Everolimus
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 19, 2023 · Synced Sep 3, 2026, 12:02 AM EDT
Recruiting Phase 1 Interventional

177Lu-PSMA-617 With Liver Directed Therapy in Metastatic Castration Resistant Prostate Cancer

NCT07145177
View directory record Official record
Conditions
Metastatic Prostate Cancer, Prostate Cancer
Interventions
177Lu-PSMA-617, Ablation, Trans-arterial chemoembolization (TACE), Positron Emission Tomography (PET)/Computerized tomography (CT), Tumor Biopsy, Questionnaire
Drug · Procedure · Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older · Male only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 31, 2026 · Synced Sep 3, 2026, 12:02 AM EDT
Recruiting Not applicable Interventional

Simulation-Free, Single-Fraction Palliative Radiation Therapy for Treatment of Bone Metastases

NCT07202273
View directory record Official record
Conditions
Bone Metastases
Interventions
simulation-free, single-fraction palliative radiation therapy
Radiation
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Sep 3, 2026, 12:02 AM EDT
Terminated Phase 1 Interventional

Evaluating the Safety and the Biological Effects of Intratumoral Interferon Gamma and a Peptide-Based Vaccine in Patients With Melanoma

NCT00977145
View directory record Official record
Conditions
Melanoma
Interventions
A combination of intratumoral IFN-gamma plus systemic vaccination with MELITAC 12.1
Biological
Lead sponsor
Craig L Slingluff, Jr
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Dec 15, 2016 · Synced Sep 3, 2026, 12:02 AM EDT
Completed Phase 2 Interventional Results available

Genotype-directed Neoadjuvant Chemoradiation for Rectal Carcinoma

NCT00682786
View directory record Official record
Conditions
Rectal Carcinoma
Interventions
5FU, Radiation, Surgery of resectable lesions, Irinotecan
Drug · Radiation · Procedure
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2010
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 5, 2017 · Synced Sep 3, 2026, 12:02 AM EDT
Completed Not applicable Interventional Results available

Determining the Benefits of Improving Communication in BPAP/CPAP Users

NCT03795753
View directory record Official record
Conditions
Positive-Pressure Respiration, Communication
Interventions
F2S Communicator, Non-functioning Communicator
Device · Other
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
3
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 17, 2020 · Synced Sep 3, 2026, 12:02 AM EDT
Completed Phase 2 Interventional

Depressed Mood Improvement Through Nicotine Dosing 3

NCT05746273
View directory record Official record
Conditions
Depressive Disorder
Interventions
Transdermal Nicotine Patch, Transdermal Placebo Patch
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
60 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Sep 3, 2026, 12:02 AM EDT
Terminated Phase 4 Interventional

Lidocaine Patch 5% Versus Celecoxib 200 mg in Chronic Axial Low Back Pain

NCT00904397
View directory record Official record
Conditions
Chronic Low Back Pain
Interventions
Lidoderm®, Celecoxib
Drug
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
18 Years and older
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
21
States / cities
Northport, Alabama • Phoenix, Arizona • Beverly Hills, California + 18 more
Source: ClinicalTrials.gov public record
Updated Feb 14, 2010 · Synced Sep 3, 2026, 12:02 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of PK, Safety, and Tolerability of 2 Lots of M207 & Intranasal Zolmitriptan in Healthy Volunteers

NCT04969497
View directory record Official record
Conditions
Migraine
Interventions
Treatment A: M207 3.8 mg "MiniMac", Treatment B: M207 3.8 mg "MACAP", Treatment C: 5.0 mg Intranasal Zolmitriptan administered at time = 0 and 2 hours post time 0
Drug
Lead sponsor
Zosano Pharma Corporation
Industry
Eligibility
18 Years to 50 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 16, 2021 · Synced Sep 3, 2026, 12:02 AM EDT
Completed Early Phase 1 Interventional Results available

Feasibility of Delivering a Quitline Based Smoking Cessation Intervention in Cancer Patients

NCT01434342
View directory record Official record
Conditions
Lung Cancer, Tobacco Use Disorder, Breast Cancer, Colorectal Cancer, Prostate Cancer
Interventions
Nicotine Replacement Patch
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 27, 2021 · Synced Sep 3, 2026, 12:02 AM EDT
Terminated Phase 2 Interventional

Efficacy of 851B Gel for Treating High-Risk Cervical Human Papillomavirus Infection in Women.

NCT00312286
View directory record Official record
Conditions
Papillomavirus Infections
Interventions
851B
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
538 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
88
States / cities
Birmingham, Alabama • Enterprise, Alabama • Huntsville, Alabama + 85 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2016 · Synced Sep 3, 2026, 12:02 AM EDT
Completed Not applicable Interventional Results available

A Pilot Randomized Controlled Trial of Financial Incentives, Text Messaging, and Usual Care for Homeless Smokers

NCT02565381
View directory record Official record
Conditions
Smoking
Interventions
Transdermal nicotine patch, In-person smoking cessation counseling, Contingent financial rewards for smoking abstinence, Text messages to support smoking abstinence
Drug · Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 13, 2017 · Synced Sep 3, 2026, 12:02 AM EDT
Completed Phase 3 Interventional Results available

A Clinical Trial to Assess the SYNERGY 48 mm Stent System for the Treatment of Atherosclerotic Lesion(s)

NCT03350542
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
SYNERGY 48 mm
Device
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
8
States / cities
Birmingham, Alabama • Saint Paul, Minnesota • New York, New York + 5 more
Source: ClinicalTrials.gov public record
Updated May 13, 2021 · Synced Sep 3, 2026, 12:02 AM EDT
Completed Not applicable Interventional

Smoking Cessation Intervention for Diabetic Patients

NCT01501877
View directory record Official record
Conditions
Smoking, Type 2 Diabetes
Interventions
Acceptance and Commitment Therapy, Standard smoking cessation intervention
Behavioral
Lead sponsor
Rhode Island Hospital
Other
Eligibility
21 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Apr 11, 2017 · Synced Sep 3, 2026, 12:02 AM EDT
Completed Not applicable Interventional Results available

The PLATINUM Clinical Trial to Assess the PROMUS Element Stent System for Treatment of De Novo Coronary Artery Lesions in Small Vessels

NCT01498692
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
PROMUS Element Coronary Stent System
Device
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
14
States / cities
Bakersfield, California • Ocala, Florida • Orlando, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Mar 25, 2019 · Synced Sep 3, 2026, 12:02 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

A Randomized Comparative Study Evaluating the Tolerability and Efficacy of Two Topical Therapies for the Treatment of Keloids and Hypertrophic Scars

NCT00754247
View directory record Official record
Conditions
Keloid, Hypertrophic Scar, Cicatrix, Hypertrophic
Interventions
0.5% hydrocortisone, silicone, vitamin E lotion, Onion extract gel, Cetearyl alcohol lotion
Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jul 9, 2019 · Synced Sep 3, 2026, 12:02 AM EDT
Completed Not applicable Interventional Results available

Hypofractionated Radiation Therapy to Improve Immunotherapy Response in Non-Small Cell Lung Cancer

NCT03035890
View directory record Official record
Conditions
Non Small Cell Lung Cancer Metastatic
Interventions
Radiation, Immuno-Therapeutic Agent
Radiation · Drug
Lead sponsor
West Virginia University
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Mar 31, 2025 · Synced Sep 3, 2026, 12:02 AM EDT
Completed Phase 2 Interventional Results available

Long-Term Follow-Up Study for Safety, Efficacy and Tolerability of Rotigotine in Adolescents With Restless Legs Syndrome

NCT01498120
View directory record Official record
Conditions
Restless Legs Syndrome
Interventions
Rotigotine
Drug
Lead sponsor
UCB BIOSCIENCES, Inc.
Industry
Eligibility
13 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
5
States / cities
Los Angeles, California • Orange, California • Spring Hill, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2017 · Synced Sep 3, 2026, 12:02 AM EDT